Shared on 02 Nov 25
Narrative Update on Cohance Lifesciences: Analyst Price Target Revision Analysts have maintained their fair value estimate for Cohance Lifesciences at ₹1,170.63 per share. They cite stable future growth expectations and unchanged profit margin forecasts.
Shared on 18 Oct 25
Fair value Decreased 3.48%New Acquisitions Will Expand Opportunities In ADCs And Oligonucleotides
Analysts have revised their price target for Cohance Lifesciences down from ₹1,213 to ₹1,171. This change reflects tempered expectations for revenue growth, partially offset by stronger profit margins.
Shared on 30 Aug 25
Fair value Decreased 2.65%New Acquisitions Will Expand Opportunities In ADCs And Oligonucleotides
Cohance Lifesciences’ consensus analyst price target saw a modest decrease to ₹1213, as both net profit margin and future P/E remained virtually unchanged, indicating stable fundamentals despite the downward revision in fair value. What's in the News Cohance Lifesciences invested USD 10 million to expand cGMP bioconjugation capabilities at its U.S. subsidiary, NJ Bio, enhancing its Antibody-Drug Conjugate (ADC) offering and supporting global innovators from early development to late-phase clinical supply.
Shared on 16 Aug 25
Fair value Decreased 5.12%New Acquisitions Will Expand Opportunities In ADCs And Oligonucleotides
The consensus analyst price target for Cohance Lifesciences has been revised downward, primarily reflecting a notable decline in net profit margin and a higher future P/E multiple, resulting in a new target of ₹1246. What's in the News Board meeting scheduled to consider and approve unaudited financial results for the quarter ending June 30, 2025.
Shared on 15 Jul 25
Fair value Decreased 17%New Acquisitions Will Expand Opportunities In ADCs And Oligonucleotides
The significant downward revision in Cohance Lifesciences’ price target reflects lowered revenue growth forecasts and a sharply higher future P/E, resulting in a new consensus fair value of ₹1313. WHAT'S IN THE NEWS Suven Pharmaceuticals Limited changed its name to Cohance Lifesciences Limited, with all company documents updated to reflect the new name.
Shared on 01 May 25
New Acquisitions Will Expand Opportunities In ADCs And Oligonucleotides
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 23 Apr 25
New Acquisitions Will Expand Opportunities In ADCs And Oligonucleotides
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
New Acquisitions Will Expand Opportunities In ADCs And Oligonucleotides
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Decreased 0.66%New Acquisitions Will Expand Opportunities In ADCs And Oligonucleotides
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 14%New Acquisitions Will Expand Opportunities In ADCs And Oligonucleotides
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Fair value Decreased 4.19%New Acquisitions Will Expand Opportunities In ADCs And Oligonucleotides
AnalystConsensusTarget has decreased revenue growth from 77.7% to 65.5% and increased profit margin from 25.3% to 30.0%.
Shared on 19 Mar 25
New Acquisitions Will Expand Opportunities In ADCs And Oligonucleotides
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 12 Mar 25
Fair value Increased 4.97%New Acquisitions Will Expand Opportunities In ADCs And Oligonucleotides
AnalystConsensusTarget made no meaningful changes to valuation assumptions.